Oral presentation of Ph 1a clinical data highlights potential best-in-class drug profile in heavily pretreated patients with PI3Ka-mutant metastatic breast cancer and other solid tumors Overall, ...
One class of drugs that has shown promise in treating diseases ranging from lung cancer to COVID-19 is targeted covalent inhibitors (TCIs). These small molecule drugs form covalent bonds with their ...
Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemia BMF-500 showed a favorable safety and tolerability ...
REDWOOD CITY, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (BMEA), a clinical-stage diabetes and obesity medicines company, today announced updated preliminary clinical data from the ...
Biomea Fusion presents preliminary Phase I clinical data for BMF-500 in treating relapsed acute leukemia at EHA 2025 Congress. Biomea Fusion, Inc. has announced updated preliminary clinical data from ...
REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent ...
Adults with insulin-deficient type 2 diabetes had a decrease in HbA1c that was maintained for 1 year after receiving a ...
1mon
Biomea Fusion Spotlights Durable Diabetes Data, Oral GLP-1 Weight-Loss Program at Oppenheimer Conf.
Biomea Fusion (NASDAQ:BMEA) outlined progress on its clinical-stage pipeline during an Oppenheimer virtual conference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results